Literature DB >> 10891438

Rapid selection of antigen-specific T lymphocytes by retroviral transduction.

G Koehne1, H F Gallardo, M Sadelain, R J O'Reilly.   

Abstract

Infusions of donor peripheral blood T cells can induce durable remissions of Epstein-Barr virus (EBV) lymphomas complicating marrow grafts, but they contain alloreactive T cells capable of inducing graft-versus-host disease. EBV-specific T-cell lines or clones avoid this problem but require 30 to 40 days of culture to establish. To accelerate the generation of EBV-specific T cells, we tested whether retroviral vectors, which only integrate in dividing cells, could be used to transduce and select antigen-reactive T cells early after sensitization to autologous EBV-transformed B cells. T cells were transduced with a dicistronic retroviral vector, NIT, which encodes low-affinity nerve growth factor receptor as an immunoselectable marker and herpes simplex virus thymidine kinase as a suicide gene, at different time points after sensitization. EBV-specific cytotoxic T lymphocyte precursor (CTLp) frequencies in purified NIT(+) T-cell fractions transduced on day 8 of culture were comparable to those of EBV-specific T-cell lines cultured for 30 days or more. Alloreactive CTLp frequencies were markedly reduced in the NIT(+) fraction relative to the untransduced T-cell population. NIT(+) fractions transduced on day 8 possessed more CD4(+) T cells than the cell lines at day 30 and exhibited the same selective pattern of reactivity against immunodominant antigens presented by specific HLA alleles. In contrast, T cells transduced with NIT 5 days after stimulation with mitogen and interleukin-2 were relatively depleted of T cells specific for autologous EBV-transformed cells. Thus, retroviral vectors may be used for rapid selection of viral antigen-reactive T cells depleted of alloreactive T cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891438

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.

Authors:  Aisha N Hasan; Wouter J Kollen; Deepa Trivedi; Annamalai Selvakumar; Bo Dupont; Michel Sadelain; Richard J O'Reilly
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

2.  Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity.

Authors:  K Liu; S A Rosenberg
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

3.  [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity.

Authors:  Pat Zanzonico; Guenther Koehne; Humilidad F Gallardo; Mikhail Doubrovin; Ekaterina Doubrovina; Ronald Finn; Ronald G Blasberg; Isabelle Riviere; Richard J O'Reilly; Michel Sadelain; Steven M Larson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-11       Impact factor: 9.236

4.  Retroviral-mediated gene transfer in primary murine and human T-lymphocytes.

Authors:  I Rivière; H F Gallardo; A B Hagani; M Sadelain
Journal:  Mol Biotechnol       Date:  2000-06       Impact factor: 2.695

5.  Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

Authors:  Juliet N Barker; Ekaterina Doubrovina; Craig Sauter; Jennifer J Jaroscak; Miguel A Perales; Mikhail Doubrovin; Susan E Prockop; Guenther Koehne; Richard J O'Reilly
Journal:  Blood       Date:  2010-09-08       Impact factor: 22.113

Review 6.  Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.

Authors:  Isabelle Rivière; Michel Sadelain
Journal:  Mol Ther       Date:  2017-04-26       Impact factor: 11.454

Review 7.  The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.

Authors:  Amy B Hont; Allison B Powell; Danielle K Sohai; Izabella K Valdez; Maja Stanojevic; Ashley E Geiger; Kajal Chaudhary; Ehsan Dowlati; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Mol Ther       Date:  2022-02-09       Impact factor: 12.910

8.  Regulatory T-cell expansion and function do not account for the impaired alloreactivity of ex vivo-expanded T cells.

Authors:  Nicolas Montcuquet; Patricia Mercier-Letondal; Sylvain Perruche; Anne Duperrier; Mélanie Couturier; Abdelghani Bouchekioua; Mark Bonyhadi; Christophe Ferrand; Pierre Tiberghien; Eric Robinet
Journal:  Immunology       Date:  2008-04-26       Impact factor: 7.397

9.  Genetic control of wayward pluripotent stem cells and their progeny after transplantation.

Authors:  Maija Kiuru; Julie L Boyer; Timothy P O'Connor; Ronald G Crystal
Journal:  Cell Stem Cell       Date:  2009-04-03       Impact factor: 24.633

10.  A self-inactivating retrovector incorporating the IL-2 promoter for activation-induced transgene expression in genetically engineered T-cells.

Authors:  Diana E Jaalouk; Laurence Lejeune; Clément Couture; Jacques Galipeau
Journal:  Virol J       Date:  2006-11-21       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.